期刊
JOURNAL OF CHEMOTHERAPY
卷 26, 期 6, 页码 333-338出版社
MANEY PUBLISHING
DOI: 10.1179/1973947813Y.0000000145
关键词
Ceftazidime-avibactam; ECOFF; Gram-negative bacteria
资金
- Educational/Research grant from AstraZeneca
- JMI Laboratories
- AstraZeneca
- Achaogen
- Aires
- American Proficiency Institute (API)
- Anacor
- Astellas
- bioMerieux
- Cempra
- Cerexa
- Contrafect
- Cubist
- Dipexium
- Enanta
- Furiex
- GlaxoSmithKline
- Johnson Johnson
- LegoChem Biosciences Inc.
- Meiji Seika Kaisha
- Nabriva
- Novartis
- Pfizer
- PPD Therapeutics
- Premier Research Group
- Rempex
- Rib-X Pharmaceuticals
- Seachaid
- Shionogi
- Medicines Co.
- Theravance
- ThermoFisher
Objectives: Ceftazidime-avibactam consists of the beta-lactam ceftazidime and the novel non-beta-lactam beta-lactamase inhibitor avibactam. The effect of avibactam on the ceftazidime MIC frequency distribution of Gram-negative European clinical isolates was observed and compared to European Committee for Antimicrobial Susceptibility Testing (EUCAST) MIC frequency distributions and epidemiological cut-off values (ECOFFs) listed for ceftazidime. Methods: Ceftazidime and ceftazidime-avibactam MICs were determined using Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution methods for Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., Serratia spp., Enterobacter spp., and Proteus mirabilis isolates collected from medical centres in Europe during 2009. Results: The MIC90 values for ceftazidime and ceftazidime-avibactam against P. aeruginosa isolates from a 2009 European surveillance programme were >32 and 8 mg/l, respectively. That is, the presence of avibactam reverted the ceftazidime MIC90 for P. aeruginosa to the ECOFF. Similarly, the MIC90 values for ceftazidime against E. coli, Klebsiella spp., Serratia spp., and P. mirabilis were also reduced to the ECOFF by the presence of avibactam. Avibactam reduced the ceftazidime MIC90 value against collected Enterobacter spp. to 1 mg/l (>32-fold reduction). No ECOFF has been defined for Enterobacter spp. however, it is 1 mg/l for Enterobacter aerogenes and Enterobacter cloacae. Conclusions: The presence of avibactam reverted the ceftazidime MIC90 for Gram-negative bacteria to the ECOFF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据